TW200519095A - Substituted fused-ring pyrimidin-4(3H)-one derivatives - Google Patents

Substituted fused-ring pyrimidin-4(3H)-one derivatives

Info

Publication number
TW200519095A
TW200519095A TW093126498A TW93126498A TW200519095A TW 200519095 A TW200519095 A TW 200519095A TW 093126498 A TW093126498 A TW 093126498A TW 93126498 A TW93126498 A TW 93126498A TW 200519095 A TW200519095 A TW 200519095A
Authority
TW
Taiwan
Prior art keywords
group
optionally substituted
alkyl group
equiv
arteriosclerosis
Prior art date
Application number
TW093126498A
Other languages
Chinese (zh)
Inventor
Masami Arai
Satoru Kaneko
Satoshi Shibuya
Tsuyoshi Watanabe
Kozo Oda
Original Assignee
Sankyo Co
X Ceptor Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sankyo Co, X Ceptor Therapeutics Inc filed Critical Sankyo Co
Publication of TW200519095A publication Critical patent/TW200519095A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541Non-condensed thiazines containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72Quinazolines; Hydrogenated quinazolines
    • C07D239/86Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88Oxygen atoms
    • C07D239/91Oxygen atoms with aryl or aralkyl radicals attached in position 2 or 3
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04Ortho-condensed systems

Abstract

The present invention provides a compound of the following formula (I) or the pharmaceutical acceptable salt or ester thereof: [wherein, A: phenyl group,heteroaryl group; R1:R1a [R1a: substituted alkyl group, optionally substituted cycloalkyl group, optionally substituted alkenyl group, optionally substituted aryl group, optionally substituted heterocyclic group], -Z1b-R1b [R1b:substituted alkyl group, optionally substituted cycloalkyl group, optionally substituted alkenyl group, optionally substituted aryl group,optionally substituted heterocyclic group,; Z1b: -NH-, -O-, -S-, -SO-, -SO2-, -CO-, -COO-, -OCO-, -CONH-, -NHCO-], -Z1c-R1c[R1c:the same as defined in R1b, alkyl group; Z1c:-C &equiv C-, -OCH2CO-, -OCOCH2O-, -OCH2CONH-, -OCH2CONMe-], -N(R1b)(R1c), -OCON(Me)2, -C &equiv CH, -C &equiv C-COMe; R2 R3: H, optionally substituted alkyl group, OH, alkoxy group, NH 2,optionally substituted amino group, nitoro group, halogen, alkylenedioxy group ;R4,R5 H, optionally substituted alkyl group, OH, alkoxy group, NH 2, SH, alkylthio group, COOH, alkoxycarbonyl group, CN, halogen;X:OH, alkoxy group; Y: optionally substituted alkyl group, optionally substituted cycloalkyl group, optionally substituted aryl group, optionally substituted arylalkyl group, optionally substituted heterocyclic group, optionally substituted heterocycloalkyl group: provided that, when Y: specific group, and A: phenyl group, then R4, R5:H; -C(CF3)2(X):-C(CF3)2(OH) which is substituted on 3 or 4 position of the phenyl group bond with]. These compounds have the exellent binding activity to LXR, and are useful as medecement, especially for treating and/or preventing arteriosclerosis, athroma arteriosclerosis, the arteriosclerosis caused by diabetes, hyperlipemia,lipid concerning diseases, inflammatory disease, or diabetes, in warm blood animals(especially human).
TW093126498A 2003-09-05 2004-09-02 Substituted fused-ring pyrimidin-4(3H)-one derivatives TW200519095A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2003314817A JP2006193426A (en) 2003-09-05 2003-09-05 Substituted condensed-ring pyrimidin-4(3h)-one compound

Publications (1)

Publication Number Publication Date
TW200519095A true TW200519095A (en) 2005-06-16

Family

ID=34269818

Family Applications (1)

Application Number Title Priority Date Filing Date
TW093126498A TW200519095A (en) 2003-09-05 2004-09-02 Substituted fused-ring pyrimidin-4(3H)-one derivatives

Country Status (3)

Country Link
JP (1) JP2006193426A (en)
TW (1) TW200519095A (en)
WO (1) WO2005023782A1 (en)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0412769D0 (en) 2004-06-08 2004-07-07 Novartis Ag Organic compounds
EP1764075A4 (en) * 2004-07-02 2010-08-04 Sankyo Co Tissue factor production inhibitor
AR056155A1 (en) * 2005-10-26 2007-09-19 Bristol Myers Squibb Co ANTAGONISTS OF NON-BASIC MELANINE CONCENTRATION HORMONE RECEIVER 1
CN101605797A (en) * 2006-11-13 2009-12-16 伊莱利利公司 The Thienopyrimidinones of treatment inflammatory disease and cancer
WO2008065754A1 (en) * 2006-11-30 2008-06-05 Kowa Company, Ltd. Substituted carbinol compound
US20080255161A1 (en) * 2007-04-11 2008-10-16 Dmitry Koltun 3-HYDROQUINAZOLIN-4-ONE DERIVATIVES FOR USE AS STEAROYL CoA DESATURASE INHIBITORS
CN101531638B (en) * 2008-03-13 2011-12-28 中国科学院广州生物医药与健康研究院 Compound used as a regulator of estrogen-related receptor and applications thereof
PE20091928A1 (en) 2008-05-29 2009-12-31 Bristol Myers Squibb Co HAVE HYDROXYSUSTITUTED PYRIMIDINES AS NON-BASIC MELANIN-CONCENTRATING HORMONE RECEPTOR-1 ANTAGONISTS
BRPI0913212A2 (en) * 2008-05-29 2019-09-24 Kowa Co carbinol compound, drug, lxr regulator, pharmaceutical composition, method for preventing and / or treating disease, and use of the carbinol derivative or salt thereof, or solvate thereof
CN103517908A (en) 2010-09-07 2014-01-15 Seoul大学校产学协力财团 Sesterterpene compounds and use thereof
JP6378630B2 (en) 2012-03-02 2018-08-22 ラレキサー セラピューティクス,インク Liver X receptor (LXR) modulators for the treatment of skin diseases, disorders, and abnormalities
EP3041835B1 (en) 2013-09-04 2020-04-08 Ellora Therapeutics, Inc. Liver x receptor (lxr) modulators
CA2923178A1 (en) 2013-09-04 2015-03-12 Alexar Therapeutics, Inc. Liver x receptor (lxr) modulators for the treatment of dermal diseases, disorders and conditions
WO2015106164A1 (en) 2014-01-10 2015-07-16 Rgenix, Inc. Lxr agonists and uses thereof
SG11201804901WA (en) 2015-12-22 2018-07-30 SHY Therapeutics LLC Compounds for the treatment of cancer and inflammatory disease
CN109069461A (en) 2016-01-11 2018-12-21 洛克菲勒大学 The treatment method of illness relevant to marrow source property inhibition cell
EA201992780A1 (en) 2017-06-21 2020-06-02 ШАЙ ТЕРАПЬЮТИКС ЭлЭлСи COMPOUNDS THAT INTERACT WITH THE RAS SUPERFAMILY FOR TREATMENT OF CANCER, INFLAMMATORY DISEASES, RAS OPATIAS AND FIBROUS DISEASE
EP3713575A4 (en) 2017-11-21 2021-08-25 Rgenix, Inc. Polymorphs and uses thereof
CA3161274A1 (en) 2019-12-13 2021-06-17 Stephen Wald Metal salts and uses thereof
JPWO2021157596A1 (en) * 2020-02-07 2021-08-12

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6316503B1 (en) * 1999-03-15 2001-11-13 Tularik Inc. LXR modulators
EP1343505A1 (en) * 2000-12-11 2003-09-17 Tularik Inc. Cxcr3 antagonists
JP2005511581A (en) * 2001-11-07 2005-04-28 メルク エンド カムパニー インコーポレーテッド Mitotic kinesin inhibitor
TW200401770A (en) * 2002-06-18 2004-02-01 Sankyo Co Fused-ring pyrimidin-4(3H)-one derivatives, processes for the preparation and uses thereof

Also Published As

Publication number Publication date
WO2005023782A1 (en) 2005-03-17
JP2006193426A (en) 2006-07-27

Similar Documents

Publication Publication Date Title
TW200519095A (en) Substituted fused-ring pyrimidin-4(3H)-one derivatives
RU2006142738A (en) CRTH2 RECEPTOR ANTAGONISTS
MY155374A (en) Aminopyrazine derivative and medicine
PE20060243A1 (en) DERIVATIVES OF 4-AMINO INSUSTITUTED-5- (4-UREA-PHENYL) -PYRROLOTRIAZINE
ATE234299T1 (en) SULFAMOYLHETEROARYLPYRAZOLE COMPOUNDS FOR USE AS ANALGESIC/ANTI-INFLAMMATORY AGENT
CY1108583T1 (en) METHOD FOR TREATMENT OF SERIOUS HEART DEFICIENCY AND MEDICINE FOR THIS
RU2007128987A (en) 5,4-AMINOPYRIDIN-2-2-Sulfur esters of 3,4-dihydro-1H-isoquinoline-2-carboxylic acid
EA200600381A1 (en) ETHYL EQUIPLASTIBLANTED ETHYLENE BETHMETBLANDBYNEETHLETHLETHLETHLETHLETHLETHLETHLETHLETHLETHLETHLETHLETHLETHLETHLETHMETHLETHMETHLETHLETHLETHMETHLETHMETHLETHMETHLETHMETHLETHMETHLETHMETHLETHMETHLETHLETHMENETHYLENEBYLENEBOOKETHLETHLENEBYLENEBOOKHABLETBOOKLETHLETHUENHUFBBBBBBB
RU2012110246A (en) SUBSTITUTED BENZOAZEPINES AS MODULATORS OF A TOLL-LIKE RECEPTOR
PE20060693A1 (en) NEW DERIVATIVES OF TRIFLUOROMETANSULFONANILIDE OXAMIDE ETER
WO2002055496A8 (en) Aryl piperidine and piperazine derivatives as inducers of ldl-receptor expression
TW200734328A (en) Aryl-isoxazolo-4-yl-imidazo [1,5-a] pyridine derivatives
JP2008510712A5 (en)
TW200505922A (en) Substituted 8-perfluoroalkyl-6,7,8,9-tetrahydropyrimido[1,2-a] pyrimidin-4-one derivatives
MA29464B1 (en) PROCESS FOR THE PREPARATION OF OPTIONALLY 2-SUBSTITUTED 1,6-DIHYDRO-6-OXO-4-PYRIMIDINECARBOXYLIC ACIDS
WO2007006534A3 (en) Piperidine derivatives useful in the diagnostic and therapeutic treatment of diseases depending on renin activity
RU2013116801A (en) NOTUM PECTINACETHYLESTERASE INHIBITORS AND WAYS OF THEIR APPLICATION
IE83426B1 (en) New pharmacologically active catechol derivatives
HU214872B (en) Process for producing pharmacologically active catechol derivatives and pharmaceutical preparations containing them
IL172290A0 (en) Use of 2-amino-1-3-propanediol derivatives for the manufacture of a medicament for the treatment of various types of pain
DK1228758T3 (en) Use of sulfodehydroabietic acid for the treatment of inflammatory bowel disease
DE60220296D1 (en) IMIDAZO (1,2-a) PYRIMIDINE AND FUNGICIDAL COMPOSITIONS CONTAINING THEREOF
TW200626571A (en) Arylsulfonylmethyl or arylsulfonamide substituted aromatic compounds suitable for treating disorders that respond to modulation of the dopamine D3 receptor
RU2001134010A (en) Optically Active Pyrrolopyridazine Derivatives
ATE321550T1 (en) MEDICAL COMPOSITIONS FOR IMMEDIATE RELEASE FOR ORAL USE